Annals of Hematology

, Volume 96, Issue 10, pp 1715–1726 | Cite as

Clinical dissection of thrombotic microangiopathy

  • Eunjeong Kang
  • Shin Hye Yoo
  • Doyeun Oh
  • Kwon Wook Joo
  • Yon Su Kim
  • Sung-Soo Yoon
  • Inho Kim
  • Seonyang Park
  • Hajeong LeeEmail author
  • Youngil KohEmail author
Original Article


Differential treatment strategies are applied in thrombotic microangiopathy (TMA) according to the sub-classifications. Hence, it is worthwhile to overview clinical manifestations and outcomes of overall TMA patients according to sub-classifications. We analyzed TMA patients whose serum lactate dehydrogenase levels >250 IU/L, with the presence of schistocytes in their peripheral blood smear, or with typical vascular pathologic abnormalities in their renal biopsy. We compared clinical manifestations including overall survival (OS) and renal survival according to TMA causes. A total of 117 TMA patients (57 primary and 60 secondary TMA) were analyzed. Renal symptom was the most common manifestation in whole patients, while renal function at diagnosis was worst in pregnancy-related TMA group. Primary TMA patients had more frequent CNS symptom and hematologic manifestation compared to secondary TMAs. Among secondary TMAs, pregnancy- and HSCT-related TMA patients showed prevalent hemolytic features. During 150.2 months of follow-up, 5-year OS rate was 64.8%. Poor prognostic factors included older age, combined hematologic and solid organ malignancies, lower hemoglobin levels, and lower serum albumin levels. There was no significant difference in OS between primary and secondary TMAs. Seventy-eight percent of patients experienced AKI during TMA. Five-year death-censored renal survival rate was poor with only 69.2%. However, excellent renal outcome was observed in pregnancy-associated TMA. TMA showed various clinical manifestations according to their etiology. Notably, both OS and renal survival were poor regardless of their etiologies except pregnancy-associated TMA. Physicians should differentiate a variety of TMA categories and properly manage this complex disease entity.


Thrombotic microangiopathy Clinical manifestation Hemolytic uremic syndrome 


Compliance with ethical standards

This study was approved by the institutional review board at our institution (number: H-1509-070-703). All procedures were performed in accordance with the principles of the Declaration of Helsinki.

Conflict of interest

The authors declare that they have no conflict of interest.

Research involving human participants

For this type of study, formal consent is not required.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Supplementary material

277_2017_3063_MOESM1_ESM.docx (16 kb)
Supplementary Table 1 (DOCX 16 kb).


  1. 1.
    George JN, Nester CM (2014) Syndromes of thrombotic microangiopathy. N Engl J Med 371:654–666CrossRefPubMedGoogle Scholar
  2. 2.
    Moake JL (2002) Thrombotic microangiopathies. N Engl J Med 347:589–600CrossRefPubMedGoogle Scholar
  3. 3.
    Barbour T, Johnson S, Cohney S, Hughes P (2012) Thrombotic microangiopathy and associated renal disorders. Nephrol Dial Transplant 27:2673–2685CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Brodsky RA (2015) Complement in hemolytic anemia. Blood 126:2459–2465CrossRefPubMedGoogle Scholar
  5. 5.
    Scully M, Cataland S, Coppo P et al (2017) Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost 15:312–322CrossRefPubMedGoogle Scholar
  6. 6.
    Shah N, Rutherford C, Matevosyan K et al (2013) Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP). Br J Haematol 163:514–519CrossRefPubMedGoogle Scholar
  7. 7.
    Jang MJ, Chong SY, Kim IH et al (2011) Clinical features of severe acquired ADAMTS13 deficiency in thrombotic thrombocytopenic purpura: the Korean TTP registry experience. Int J Hematol 93:163–169CrossRefPubMedGoogle Scholar
  8. 8.
    Group KDIGOKAKIW (2012) KDIGO clinical practice guideline for acute kidney injury. Kidney Inter (Suppl.): 1–138Google Scholar
  9. 9.
    von Baeyer H (2002) Plasmapheresis in thrombotic microangiopathy-associated syndromes: review of outcome data derived from clinical trials and open studies. Ther Apher 6:320–328CrossRefGoogle Scholar
  10. 10.
    Saultz JN, Wu HM, Cataland S (2015) Headache prevalence following recovery from TTP and aHUS. Ann Hematol 94:1473–1476CrossRefPubMedGoogle Scholar
  11. 11.
    Martinez MT, Bucher C, Stussi G et al (2005) Transplant-associated microangiopathy (TAM) in recipients of allogeneic hematopoietic stem cell transplants. Bone Marrow Transplant 36:993–1000CrossRefPubMedGoogle Scholar
  12. 12.
    Jodele S, Laskin BL, Dandoy CE et al (2015) A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury. Blood Rev 29:191–204CrossRefPubMedGoogle Scholar
  13. 13.
    Hosler GA, Cusumano AM, Hutchins GM (2003) Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases. Arch Pathol Lab Med 127:834–839PubMedGoogle Scholar
  14. 14.
    Eremina V, Cui S, Gerber H et al (2006) Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival. J Am Soc Nephrol 17:724–735CrossRefPubMedGoogle Scholar
  15. 15.
    Markowitz GS, Bomback AS, Perazella MA (2015) Drug-induced glomerular disease: direct cellular injury. Clin J Am Soc Nephrol 10:1291–1299CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Noris M, Remuzzi G (2010) Thrombotic microangiopathy after kidney transplantation. Am J Transplant 10:1517–1523CrossRefPubMedGoogle Scholar
  17. 17.
    Kavanagh D, Goodship TH, Richards A (2013) Atypical hemolytic uremic syndrome. Semin Nephrol 33:508–530CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Nayer A, Asif A (2016) Atypical hemolytic-uremic syndrome: a clinical review. Am J Ther 23:e151–e158CrossRefPubMedGoogle Scholar
  19. 19.
    Dahlan R, Sontrop JM, Li L et al (2015) Primary and secondary thrombotic microangiopathy referred to a single plasma exchange center for suspected thrombotic thrombocytopenic purpura: 2000-2011. Am J Nephrol 41:429–437CrossRefPubMedGoogle Scholar
  20. 20.
    Uderzo C, Bonanomi S, Busca A et al (2006) Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Transplantation 82:638–644CrossRefPubMedGoogle Scholar
  21. 21.
    Laskin BL, Goebel J, Davies SM, Jodele S (2011) Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Blood 118:1452–1462CrossRefPubMedGoogle Scholar
  22. 22.
    Karthikeyan V, Parasuraman R, Shah V et al (2003) Outcome of plasma exchange therapy in thrombotic microangiopathy after renal transplantation. Am J Transplant 3:1289–1294CrossRefPubMedGoogle Scholar
  23. 23.
    de Fontbrune FS, Galambrun C, Sirvent A et al (2015) Use of eculizumab in patients with allogeneic stem cell transplant-associated thrombotic microangiopathy: a study from the SFGM-TC. Transplantation 99:1953–1959CrossRefPubMedGoogle Scholar
  24. 24.
    Bridoux F, Vrtovsnik F, Noel C et al (1998) Renal thrombotic microangiopathy in systemic lupus erythematosus: clinical correlations and long-term renal survival. Nephrol Dial Transplant 13:298–304CrossRefPubMedGoogle Scholar
  25. 25.
    Zafrani L, Mariotte E, Darmon M et al (2015) Acute renal failure is prevalent in patients with thrombotic thrombocytopenic purpura associated with low plasma ADAMTS13 activity. J Thromb Haemost 13:380–389CrossRefPubMedGoogle Scholar
  26. 26.
    Caprioli J, Noris M, Brioschi S et al (2006) Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 108:1267–1279CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Ritz E, Orth SR (1999) Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 341:1127–1133CrossRefPubMedGoogle Scholar
  28. 28.
    Krolewski M, Eggers PW, Warram JH (1996) Magnitude of end-stage renal disease in IDDM: a 35 year follow-up study. Kidney Int 50:2041–2046CrossRefPubMedGoogle Scholar
  29. 29.
    Chou YH, Lien YC, Hu FC et al (2012) Clinical outcomes and predictors for ESRD and mortality in primary GN. Clin J Am Soc Nephrol 7:1401–1408CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Frimat L, Briancon S, Hestin D et al (1997) IgA nephropathy: prognostic classification of end-stage renal failure. L’Association des Nephrologues de l'Est. Nephrol Dial Transplant 12:2569–2575CrossRefPubMedGoogle Scholar
  31. 31.
    Lee H, Hwang JH, Paik JH et al (2014) Long-term prognosis of clinically early IgA nephropathy is not always favorable. BMC Nephrol 15:94CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Xie J, Kiryluk K, Wang W et al (2012) Predicting progression of IgA nephropathy: new clinical progression risk score. PLoS One 7:e38904CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Jin DC, Yun SR, Lee SW et al (2015) Lessons from 30 years’ data of Korean end-stage renal disease registry, 1985-2015. Kidney Res Clin Pract 34:132–139CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Vilalta R, Lara E, Madrid A et al (2012) Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome. Pediatr Nephrol 27:2323–2326CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Gediz F, Payzin BK, Ecemis S et al (2016) Efficacy and safety of eculizumab in adult patients with atypical hemolytic uremic syndrome: a single center experience from Turkey. Transfus Apher Sci 55:357–362CrossRefPubMedGoogle Scholar
  36. 36.
    George JN, Al-Nouri ZL (2012) Diagnostic and therapeutic challenges in the thrombotic thrombocytopenic purpura and hemolytic uremic syndromes. Hematol Am Soc Hematol Educ Program 2012:604–609Google Scholar
  37. 37.
    Bae WK, Lee YK, Cho MS et al (2006) A case of hemolytic uremic syndrome caused by Escherichia coli O104:H4. Yonsei Med J 47:437–439CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  • Eunjeong Kang
    • 1
  • Shin Hye Yoo
    • 1
  • Doyeun Oh
    • 2
  • Kwon Wook Joo
    • 3
    • 4
  • Yon Su Kim
    • 3
    • 4
  • Sung-Soo Yoon
    • 5
  • Inho Kim
    • 5
  • Seonyang Park
    • 5
  • Hajeong Lee
    • 3
    • 4
    Email author
  • Youngil Koh
    • 5
    Email author
  1. 1.Department of Internal MedicineSeoul National University College of MedicineSeoulSouth Korea
  2. 2.Division of Hematology-oncology, Department of Internal MedicineCHA University School of MedicineSeongnamSouth Korea
  3. 3.Division of Nephrology, Department of Internal MedicineSeoul National University College of MedicineSeoulSouth Korea
  4. 4.Kidney Research InstituteSeoul National University College of MedicineSeoulSouth Korea
  5. 5.Division of Hematology, Department of Internal MedicineSeoul National University College of MedicineSeoulSouth Korea

Personalised recommendations